VIGAMOX SUMMARY
VIGAMOX® (moxifloxacin hydrochloride ophthalmic solution) 0.5% is a sterile solution for topical ophthalmic use. Moxifloxacin hydrochloride is an 8-methoxy fluoroquinolone anti-infective, with a diazabicyclononyl ring at the C7 position.
VIGAMOX® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
Corynebacterium species*
Micrococcus luteus*
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus haemolyticus
Staphylococcus hominis
Staphylococcus warneri*
Streptococcus pneumoniae
Streptococcus viridans group
Acinetobacter lwoffii*
Haemophilus influenzae
Haemophilus parainfluenzae*
Chlamydia trachomatis
*Efficacy for this organism was studied in fewer than 10 infections.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Vigamox (Moxifloxacin)
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. [2014] uncomplicated, smear-positive pulmonary tuberculosis... CONCLUSIONS: The two moxifloxacin-containing regimens produced a more rapid
Efficacy and safety of moxifloxacin in hospitalized patients with secondary
peritonitis: pooled analysis of four randomized phase III trials. [2014] bacteria... CONCLUSIONS: The data suggests that once-daily IV (or IV/PO) moxifloxacin has a
Randomised clinical trial of moxifloxacin versus ertapenem in complicated
intra-abdominal infections: results of the PROMISE study. [2013] Antibiotic therapy for complicated intra-abdominal infections (cIAIs) should
provide broad-spectrum coverage both Gram-positive and Gram-negative
microorganisms... The results show that moxifloxacin is a valuable treatment option for a range of
community-acquired cIAIs with mild-to-moderate severity.
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and
moxifloxacin combinations: a randomised trial. [2012] first 14 days of treatment to assess their suitability for future development... INTERPRETATION: PA-824-moxifloxacin-pyrazinamide is potentially suitable for
Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: a randomized controlled trial. [2011.10.03] OBJECTIVES: (i) the inflammatory response to CPB may be different from that of infectious disease states that were used to establish the immunomodulatory effects of moxifloxacin; and (ii) a single intravenous dose, which was used in this investigation, may not lead to high enough plasma and intracellular concentrations..
Clinical Trials Related to Vigamox (Moxifloxacin)
Food and Insulin Effect on QT/QTC Interval of ECG [Completed]
Moxifloxacin is routinely used as a probe to confirm assay sensitivity in thorough
electrocardiogram (ECG) studies. It has been shown that a meal shortens the QT interval,
which may affect pharmacokinetics (PK) and/or pharmacodynamics (PD) of the study drug.
However, there is no published data clarifying this issue. There is also a paucity of data
investigating ethnic differences of the effects of medicines on QTc.
The aims of the study were to compare the effect of different food contents to placebo on
the changes in ECG and to demonstrate the effect of insulin, C-peptide and glucose on the
ECG. This was done by giving different treatments on separate days, which included
intravenous insulin, a high carbohydrate breakfast [>70%], and a calorie reduced low
carbohydrate American FDA standard breakfast. Moxifloxacin 400 mg was used as a positive
control and was given with and without food to Caucasian and Japanese volunteers to
investigate racial differences.
Effect on Wound Healing of Vigamox Versus Cravit [Completed]
The purpose of this study was to compare the effects of Vigamox and Cravit on corneal wound
healing after cataract surgery.
Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification [Recruiting]
The purpose of this study is to compare drug concentrations in aqueous humor following
ocular instillation of Besivance and VIGAMOX in subjects undergoing cataract surgery.
Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients [Completed]
The purpose of this study is to describe the pharmacokinetics of moxifloxacin in children to
see what the best dose should be for children in the future. Pharmacokinetics is to see how
the body absorbs, distributes, breaks down and gets rid of the study drug. The
pharmacokinetics of certain drugs may be altered in children due to developmental
differences in various organ functions responsible for drug elimination, as well as in
general distribution characteristics. The safety of moxifloxacin in children with
infections will also be looked at. Results from this study will be used to guide dosing
strategies of the larger clinical trial planned for children
Bioequivalence of Eye Drops and Spray Administration of Vigamox [Completed]
The study compares the amounts of Vigamox absorbed when administered as eye drops or in a
spray form. Both administrations will be prior to patients undergoing elective cataract
surgery and the aqueous samples will be analyzed by a laboratory in a masked fashion. The
hypothesis is that there will be no difference between the 2 modes of administration.
Reports of Suspected Vigamox (Moxifloxacin) Side Effects
Toxic Anterior Segment Syndrome (85),
Endophthalmitis (33),
OFF Label USE (31),
Eye Pain (21),
Visual Acuity Reduced (17),
Medication Error (16),
Vitritis (14),
Eye Irritation (10),
Retinal Detachment (10),
Post Procedural Complication (8), more >>
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Vigamox has an overall score of 10. The effectiveness score is 10 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
| Vigamox review by 27 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Highly Effective |
Side effects: | | No Side Effects | | Treatment Info |
Condition / reason: | | conjunctivitus |
Dosage & duration: | | 2-3 drops (dosage frequency: 2-3 x a day) for the period of 5 days |
Other conditions: | | n/a |
Other drugs taken: | | n/a | | Reported Results |
Benefits: | | The rx cleared up my conjunctivitus. It was fast & easy to use. I was surpised @ how quickly it worked. It does sting when you use but on the other hand as soon as the pink eye goes away it doesnt sting anymore. |
Side effects: | | It stings a little & you can't wear contacts until its over. |
Comments: | | you get a 3 ml eye drop bottle & use 1-2 drops 2-3 x a day until it goes away. I still have half a bottle left. |
|
|
Page last updated: 2015-08-10
|